Case Report of Patients with Acute Respiratory Distress Syndrome Caused by COVID-19: Successfully Treated by Venovenous Extracorporeal Membrane Oxygenation and an Ultra-Protective Ventilation

Medicina (Kaunas). 2020 Oct 29;56(11):570. doi: 10.3390/medicina56110570.

Abstract

Coronavirus disease (COVID-19) started in Wuhan (China) at the end of 2019, and then increased rapidly. In patients with severe acute respiratory distress syndrome (ARDS) caused by COVID-19, venovenous extracorporeal membrane oxygenation (VV-ECMO) is considered a rescue therapy that provides adequate gas exchange. The way in which mechanical ventilation is applied during VV-ECMO is not clear, however it is associated with prognosis. Currently, the mortality rate of COVID-19 patients that receive VV-ECMO stands at approximately 50%. Here, we report three patients that successfully recovered from COVID-19-induced ARDS after VV-ECMO and implementation of an ultra-protective ventilation. This ventilation strategy involved maintaining a peak inspiratory pressure of ≤20 cmH2O and a positive end-expiratory pressure (PEEP) of ≤ 10 cmH2O, which are lower values than have been previously reported. Thus, we suggest that this ultra-protective ventilation be considered during VV-ECMO as it minimizes the ventilator-induced lung injury.

Keywords: COVID-19; acute respiratory distress syndrome; ultra-protective ventilation; venovenous extracorporeal membrane oxygenation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / therapy*
  • Extracorporeal Membrane Oxygenation / methods*
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunization, Passive
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / therapy*
  • Respiration, Artificial / methods*
  • Respiratory Distress Syndrome / therapy*
  • SARS-CoV-2
  • Ventilator-Induced Lung Injury / prevention & control*

Substances

  • Anti-Bacterial Agents
  • Antiviral Agents
  • Glucocorticoids